Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics focused on the microbiome. The Company's lead gut microbiome-focused programs poised for Phase 3 development include SYN-004 (ribaxamase), designed to protect the gut microbiome from the deleterious effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of primary C. difficile infection, antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial resistance (AMR), and SYN-010 a proprietary, modified-release formulation of lovastatin lactone intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
DDW Tracks Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees? No
Is your company a new exhibiting company? Yes